PAT-SM6, an anti-GRP78 antibody, has demonstrated potent anti-tumoral activity in preclinical models and has progressed to phase I clinical trials in patients with malignant melanoma (Hensel et al. 2013). This evidence concerns the gene HSPA5 and melanoma.